Researchers at Tel Aviv University have discovered that cancerous tumors can hijack immune cells, specifically macrophages, to accelerate their own growth. By using a new technology called Effero-seq, the team found that macrophages, which normally clear dead cells, are “reprogrammed” after consuming dead cancer cells to support tumor development and suppress anti-cancer immune activity. According to the study published in Science Immunology, this process helps tumors build new blood vessels to secure oxygen and nutrients.
How do macrophages fuel tumor growth?
Macrophages are immune cells typically tasked with cleaning up damaged or dead tissue. However, Dr. Merav Cohen and her team at Tel Aviv University’s Gray Faculty of Medical and Health Sciences found that this function backfires in the presence of cancer. When these cells consume dead cancer cells, they undergo a genetic shift. Instead of maintaining healthy tissue, they begin activating genes that promote tumor expansion. This discovery, detailed in Science Immunology, provides a clearer picture of how tumors manipulate the body’s internal defense system to survive.
Macrophages are often called the “garbage collectors” of the immune system. In a healthy body, they prevent inflammation by removing cellular debris, but cancer cells can exploit this routine to receive a supply of vital nutrients.
What is the Effero-seq technology?
To track these changes, the researchers developed a specialized tool known as Effero-seq. This technology allows scientists to observe exactly how immune cells behave after engulfing dead cells. By using a melanoma model, the team proved that macrophages that had consumed dead cancer cells actively encouraged the growth of new blood vessels within the tumor. These blood vessels act as a pipeline, delivering oxygen and nutrients that allow the cancer to grow more rapidly.
Does this impact patient survival rates?
The research team expanded their scope to include data from patients with uveal melanoma, a type of eye cancer. Their findings suggest a correlation between this immune cell behavior and clinical outcomes. Patients whose tumors contained higher levels of macrophages with this specific “reprogrammed” genetic signature generally faced lower survival rates. This data reinforces the theory that the tumor’s ability to influence the immune system is a significant factor in disease progression.
Pro Tip: Understanding the Immune Microenvironment
When evaluating cancer progression, clinicians are increasingly looking beyond the tumor cells themselves. Monitoring the state of surrounding macrophages may eventually offer a way to predict how aggressively a cancer will behave, according to insights provided by Dr. Cohen’s research.
What are the future treatment implications?
Dr. Cohen notes that these findings identify a potential new target for cancer therapies. Current treatments often focus exclusively on destroying cancer cells, but this research highlights the need to also block the mechanisms that allow tumors to “recruit” the immune system. By preventing the reprogramming of macrophages, future therapies could potentially restore the immune system’s natural ability to recognize and fight cancer.
Frequently Asked Questions
- What are macrophages?
Macrophages are immune cells that protect the body by removing dead or damaged cells and cellular debris. - How do tumors grow faster?
According to the Tel Aviv University study, tumors can trigger macrophages to build new blood vessels, which provide the tumor with increased oxygen and nutrients. - What is the significance of the Effero-seq method?
Effero-seq is a new technology that tracks how immune cells change their gene expression after consuming dead cells, helping researchers identify how cancer manipulates the immune system. - Can this lead to new cancer treatments?
Yes. Researchers believe that if they can block the mechanism that reprograms macrophages, they may be able to restore the immune system’s ability to combat tumors.
Are you interested in the latest advancements in cancer research? Subscribe to our newsletter for updates on how new technologies are changing the way we treat complex diseases, or explore our science archive for more in-depth reports.
